Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Nivolumab and relatlimab-rmbw + XTX101 |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Nivolumab and relatlimab-rmbw | Opdualag | BMS-986213 | LAG3 Antibody 20 PD-L1/PD-1 antibody 140 | Opdualag (nivolumab and relatlimab-rmbw) is a fixed-dose combination of Relatlimab (BMS-986016) and Opdivo (nivolumab), which may lead to enhanced anti-tumor immune response (PMID: 34986285). Opdualag (nivolumab and relatlimab-rmbw) is FDA approved for use in adult and pediatric patients of 12 years or older with unresectable or metastatic melanoma (FDA.gov). |
| XTX101 | XTX 101|XTX-101|Vilastobart | CTLA4 Antibody 34 | XTX101 is an anti-CTLA4 antibody engineered for tumor microenvironment-specific activity, which may lead to proliferation of CD8+ T lymphocytes, activation of T lymphocyte function, and tumor regression (Journal for ImmunoTherapy of Cancer 2020;8) |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07896811 | Phase II | Nivolumab and relatlimab-rmbw + XTX101 | Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma (TRIFECTA-SCC) | Not yet recruiting | USA | 0 |
CKB BOOST